Associate Professor
WANG Lifei
Source:
time：2021-12-13
Views：
Name：Lifei Wang
Department：NHC Key Laboratory of Biotechnology of Antibiotics, CAMS Key Laboratory of Synthetic Biology for Drug Innovation
Tel: (8610)63188604
Email: wanglifei@imb.pumc.edu.cn
Education & Research
Education/Training
09/2005 - 07/2008 Peking Union Medical College (PUMC), Microbiology & Biochemical Pharmacy, Ph.D.
09/2001 - 01/2004 Peking Union Medical College (PUMC), Microbiology & Biochemical Pharmacy, M.S.
09/1998 - 07/2001 Peking Union Medical College (PUMC), Clinical Medicine, B.A.
Positions and Employment
2012- Associate Professor
Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC)
2004-2011 Assistant Professor
Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC)
1994-2003 Research Associate
Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC)
Research Field：
1. Discovery of new targets for tumor immunotherapy
2. Research on the synthesis biology of secondary metabolites
Research Interests：
Dr. Wang’s research work mainly focuses on the following five research directions:
1. Discovery of new targets for tumor immunotherapy
During her visit to the United States, she has been engaged in research on cancer genome, targeted gene identification, oncomics and tumor immunity. In 2017, she started the project on "The role of MAL2 in tumor immunosuppression of triple negative subtype breast cancer", and found a new potential target gene MAL2 for tumor immunotherapy in triple negative breast cancer. MAL2 promotes the endocytosis of MHC-I complex and reduces the presentation of tumor antigen on cell surface through direct interaction with MHC-I complex and endosome related Rab protein. MAL2 work has been published in the Journal of Clinical Investigation (IF: 11.8) in 2021. Due to its outstanding novelty, it was selected as the cover article of Journal and commented as a possible new cancer treatment target by Devin Dersh and Jonathan Yewedell.
2. Study on the anti-inflammatory mechanism of Epstein
Her research on the anti-inflammatory mechanism of Ebosin, a natural product with new structure and independent intellectual property rights in China, is novel and unique, revealing the possible anti-inflammatory mechanism of this kind of polysaccharide. The work has been published in cellular & Molecular Immunology (IF: 8.2).
3. Regulation mechanism of microbial secondary metabolite biosynthesis
She worked on the biosynthesis and regulation mechanism of lidamycin, sansanmycin, norvancomycin and other antibiotics which produced by Strptomycetes. The detailed study of the control of biosynthesis will shed light on the metabolic engineering of the super high-yield strain and provide the theoretical basis for using synthesis biology approaches to develop novel drugs.
Grant Support
1. Agency: CAMS Innovation Fund for Medical Sciences (2016-I2M-3-012). （1,890,000 RMB）
Title: Analysis and Recombination of Glycosyl Receptor (glycon) Biosynthetic Pathway
Duration: 1/1/2016-12/31/2020
Role: Principal Investigator
2. Agency: National Mega-project for Innovative Drugs (2014ZX09201001-004-001) （2,570,000 RMB）
Title: Rational Construction of High Producing Norvancomycin Strain using Synthetic Biology Method
Duration: 1/1/2014-12/31/2016
Role: Principal Investigator
3. Agency: National Natural Science Foundation of China (81302677) （230,000 RMB）
Title: Genomic Mining for Streptomyces globisporus C-1027 Natural Products
Duration: 1/1/2014-12/31/2016
Role: Principal Investigator
4. Agency: The Fundamental Research Funds for the Central Universities (3332013088) （100,000 RMB）
Title: Genomic Mining for Streptomyces globisporus C-1027 Natural Products
Duration: 7/1/2013-6/31/2014
Role: Principal Investigator
5. Agency: National Natural Science Foundation of China (30973668) （320,000 RMB）
Title: Mechanism of Coordinated Expression of Apoprotein and Production of Chromophore for Biosynthesis Lidamycin
Duration: 1/1/2010-12/31/2012
Role: Principal Investigator
6. Agency: Beijing Natural Science Foundation (5102032) （110,000 RMB）
Title: Characterization of sgcR in Lidamycin Biosynthesis and Its Application in Metabolic Engineering
Duration: 1/1/2010-12/31/2012
Role: Principal Investigator
Selected Publications
1.YuanzhangFang#, Lifei Wang#, Changlin Wan#, Yifan Sun,Kevin Van der Jeught, Zhuolong Zhou, Tianhan Dong, Ka Man So, Tao Yu, YujingLi, Haniyeh Eyvani, Austyn B. Colter, Edward Dong, Sha Cao, Jin Wang, Bryan P. Schneider, George E. Sandusky, Yunlong Liu, Chi Zhang*, Xiongbin Lu*, and XinnaZhang*. MAL2 drives immune evasion in breast cancer bysuppressing tumor antigen presentation. J Clin Invest. 2021 Jan 4;131(1):e140837. doi: 10.1172/JCI140837.（IF：11.8 cover）
2. Xingxing Li, Cong Zhang, Ying Zhao, Xuan Lei, ZhiboJiang, Xuexia Zhang, Zhihui Zheng, Shuyi Si, Lifei Wang* and Bin Hong*. Comparative genomics and transcriptomics analyses provide insights into the high yield and regulatory mechanism of Norvancomycin biosynthesis in Amycolatopsis orientalis NCPC 2-48.MicrobCell Fact (2021) 20:28 https://doi.org/10.1186/s12934-021-01521-6（IF：4.4）
3. Xingxing Li, Cong Zhang, Xuan Lei, Lifei Wang*, Bin Hong*. Draft Genome Sequence of Teicoplanin-Producing Strain Actinoplanesteichomyceticus CPCC 203265. Microbiol Resour Announc. 2019 Oct 10;8(41). pii:e01091-19. doi: 10.1128/MRA.01091-19.
4. Yuanyuan Shi#, Renjie Gu#, Yihong Li, Xinwei Wang,Weicong Ren, Xingxing Li, Lifei Wang, Yunying Xie*, Bin Hong*. Exploring novel herbicidin analogues by transcriptional regulator overexpression and MS/MS molecular networking. Microbial Cell Factories, 2019（IF：4.4）
4. Zhibo Jiang#, Weicong Ren#, Yuanyuan Shi, XingxingLi, Xuan Lei, Jiahui Fan, Cong Zhang, Renjie Gu, Lifei Wang, YunyingXie*, Bin Hong*. Structure-based manual screening and automatic networking for systematically exploring sansanmycin analogues using high performance liquid chromatography tandem mass spectroscopy. Journal of Pharmaceutical and Biomedical Analysis, 2018, 158, 94-105.(IF：2.831)
5. Yang Zhang#, Lifei Wang#, Yuan Li. Ebosin: apotential therapeutic agent for rheumatoid arthritis and autoinflammatory syndromes. Cell Mol Immunol. 2018 Jan;15(1):12-14. (IF：8.213)
6. Li Y, Liu Y, Xu H, Jiang G, Van der Jeught K, FangY, Zhou Z, Zhang L, Frieden M, Wang L, Luo Z, Radovich M, Schneider BP, Deng Y, Liu Y, Huang K, He B, Wang J, He X, Zhang X, Ji G, Lu X. Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II. Nat Commun. 2018 Oct 22;9(1):4394. doi:10.1038/s41467-018-06811-z. (IF：12.19)
7. Liu Y, Xu J, Choi HH, Han C, Fang Y, Li Y, Van der Jeught K, Xu H, Zhang L, Frieden M, Wang L, Eyvani H, Sun Y1, Zhao G, Zhang Y, Liu S, Wan J, Huang, Ji G, Lu X, He X, Zhang X. Targeting 17q23amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breas tcancer. Nat Commun. 2018 Nov 9;9(1):4718. doi: 10.1038/s41467-018-07264-0.(IF：12.19)
8. Xuan Lei, Cong Zhang, Zibin Jiang, X Li, Yuanyuan Shi, Ming Liu, Yunying Xie, Lifei Wang*, Bin Hong. Complete genomesequence of Amycolatopsis orientalis CPCC200066, the producer of norvancomycin. J Biotechnol. 2017 Apr 10;247:6-10.(IF：2.834)
9. Zibin Jiang, Xuan Lei, Minghua Chen, Binya Jiang, Linzhuan Wu, Xuexia Zhang, Zhihui Zheng, Xinxin Hu, Xuefu You, Shuyi Si, Lifei Wang*, Bin Hong*. Three structurally-related impurities innorvancomycin drug substance. J Antibiot (Tokyo). 2017 Feb;70(2):158-165. (IF：2.237)
10. Xingxing Li, Xuan Lei, Cong Zhang, Zhibo Jiang, Yuanyuan Shi, Songmei Wang, Lifei Wang*, Bin Hong*. Complete genome sequence of Streptomyces globisporus C-1027, the producer of an enediyne antibiotic lidamycin. J Biotechnol. 2016 Mar 20;222:9-10. doi: 10.1016/j.jbiotec.2016.02.004. Epub 2016 Feb 4. (IF：2.834)
11. Yuanyuan Shi, Zhibo Jiang, Xuan Lei, Ningning Zhang, Qiang Cai, Qinglian Li, Shuyi Si, Lifei Wang, Yunying Xie*, Bin Hong*. Improving the N-terminal diversity of sansanmycin through mutasynthesis. Microb Cell Fact. 2016 May 6;15:77. (IF：4.4)
12. Xuan Lei, Fang Yuan, Yuanyuan Shi, Xingxing Li, Lifei Wang*, Bin Hong*. Draft genome sequenceof norvancomycin-producing strain Amycolatopsis orientalis CPCC200066. Genome Announc. 2015 May 14;3(3).
13. Yang Zhang#, Lifei Wang#，Liping Bai, Rong Jiang, Lianhong Guo, Jianbo Wu, Guifang Cheng, Ren Zhang and Yuan Li. Effect of ebosin on modulating interleukin-1β-induced inflammatory responses in rat fibroblast-like synoviocytes. Cellular & Molecular Immunology (2015), 1–9 (IF：8.213)
14. Xingxing Li, Tengfei Yu, Qing He, KJ McDowall, Bingya Jiang, Zhibo Jiang, Linzhuan Wu, Guangwei Li, QinglianLi, Songmei Wang, Yuanyuan Shi, Lifei Wang*, Bin Hong*. Binding of a biosynthetic intermediate to AtrA modulates the production of lidamycin by Streptomyces globisporus. Mol Microbiol. 2015 Mar 19. doi: 10.1111/mmi.13004. [Epub ahead of print] (IF：3.761)（F1000）
Awards and Honors
"Research on the expression characteristics of Streptomyces lividans TK24 sece promoter" was selected as an excellent paper in the Conference Commemorating the 50th anniversary of DNA model publication and the 30th anniversary of the founding of Acta genetics.
2013 advanced worker of Institute of Medicinal Biotechnology
Academic Appointments
Guest editor of Journal of Immunology Research
Reviewer of National Natural Science Foundation of China
Reviewer of Beijing Natural Science Foundation
Thesis reviewer of The Ministry of Education Graduate and Education Development Center
